Jane Pritchett Henderson

Jane Pritchett Henderson has been working in the pharmaceutical industry since 2010. Jane began their career at ISTA Pharmaceuticals as Vice President of Business Development, where they were responsible for rapidly growing the company's branded prescription eye care business in the United States and an emerging allergy drug franchise. Jane also coordinated the successful defense against a hostile bid from Valeant and drove all aspects of the strategic option process resulting in the acquisition of ISTA by Bausch + Lomb.

In 2013, Henderson moved to Kolltan Pharmaceuticals, Inc., where they held the position of Senior Vice President, Chief Financial & Business Officer. Jane then moved to Voyager Therapeutics, Inc. in 2017 as Chief Financial Officer and Senior Vice President, Corporate Development.

In 2018, Henderson joined Turnstone Biologics as Chief Financial Officer and Sesen Bio (formerly Eleven Biotherapeutics) as Board of Directors Member, Chair of the Audit Committee. Jane also joined Iveric Bio as Board of Directors Member, Chair of Audit Committe.

In 2020, Henderson joined Adagio Therapeutics as Chief Financial Officer & Chief Business Officer. The following year, they joined Ventus Therapeutics as Member, Board of Directors, Chair of Audit Committee. Most recently, Henderson joined Apogee Therapeutics in 2023 as Chief Financial Officer.

Jane Pritchett Henderson attended Duke University from 1983 to 1987, where they obtained a Bachelor of Science in Psychology and a Bachelor of Science (B.S.).